This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

This study has been completed.
Information provided by:
The University of Texas Medical Branch, Galveston Identifier:
First received: November 16, 2009
Last updated: July 13, 2011
Last verified: July 2011
The long-term objective of this research is to develop a non-invasive approach for early assessment of which patients are at high risk for future development of skeletal muscle atrophy. The investigators hypothesize that the rate constant for the terminal portion of the isotope decay curve following ingestion of a single oral dose of deuterated-3-methylhistidine (D-3MH) provides an accurate measure of this increased risk and that this rate constant can be measured non-invasively from timed spot urine samples.


Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Non-invasive Assessment of Skeletal Muscle Loss in Cancer Patients

Further study details as provided by The University of Texas Medical Branch, Galveston:

Estimated Enrollment: 10
Study Start Date: October 2009
Healthy control male


Ages Eligible for Study:   30 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
community sample of healthy males

Inclusion Criteria:

  • Male
  • 30-75 years old
  • Body Mass Index (BMI) <27 kg/m2

Exclusion Criteria:

  • Uncontrolled hypertension
  • Glomerular filtration rate less than 60 mL/min/1.73 m2
  • History of recurrent gastrointestinal bleeding
  • Unable or unwilling to provide informed consent
  • Ongoing anti-coagulant therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01015274

United States, Texas
University of Texas Medical Branch
Galveston, Texas, United States, 77555
Sponsors and Collaborators
The University of Texas Medical Branch, Galveston
Principal Investigator: Morteza Janghorbani, Ph.D. BIOCHEMANALYSIS CORPORATION
Study Director: Melinda Sheffield-Moore, Ph.D. University of Texas
  More Information

Responsible Party: Morteza Janghorbani, Ph.D., BIOCHEMANALYSIS CORPORATION, Chicago, IL Identifier: NCT01015274     History of Changes
Other Study ID Numbers: 09-150
1R43AR054993-01 ( U.S. NIH Grant/Contract )
Study First Received: November 16, 2009
Last Updated: July 13, 2011

Additional relevant MeSH terms:
Weight Loss
Body Weight Changes
Body Weight
Signs and Symptoms processed this record on August 18, 2017